Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells

Hongmiao Sheng, Jinyi Shao, Jason D. Morrow, R. Daniel Beauchamp, Raymond N. DuBois

Research output: Contribution to journalArticle

1066 Citations (Scopus)

Abstract

Previously, we have shown that forced expression of prostaglandin endoperoxide synthase-2 [also called cyclooxygenase (COX) 2] leads to inhibition of programmed cell death in intestinal epithelial cells. More recently, we have demonstrated that growth of human colonic cancer xenografts is inhibited by treatment with a highly selective COX-2 inhibitor in tumors that express COX-2 (HCA-7) but not in those that lack COX-2 expression (HCT- 116). To explore the biochemical mechanisms involved in these effects, we have evaluated the role of COX-2-derived eicosanoid products on programmed cell death in human colon cancer cells. Here we report that PGE2 treatment of human colon cancer cells leads to increased clonogenicity of HCA-7, but not HCT-116 cells. Treatment with a highly selective COX-2 inhibitor (SC- 58125) decreases colony formation in monolayer culture and this growth inhibition was reversed by treatment with PGE2. Additionally, PGE2 inhibits programmed cell death caused by SC-58125 and induces Bcl-2 expression, but did not affect Bcl-x or Bax expression in human colon cancer (HCA-7) cells. Therefore, decreased cell death caused by PGE2 would enhance the tumorigenic potential of intestinal epithelial cells. Thus, these results may help to explain a component of the mechanism by which COX inhibitors prevent colorectal cancer in humans.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalCancer Research
Volume58
Issue number2
StatePublished - Jan 15 1998
Externally publishedYes

Fingerprint

Dinoprostone
Colonic Neoplasms
Cyclooxygenase 2
Apoptosis
Cell Death
Cyclooxygenase 2 Inhibitors
Epithelial Cells
HCT116 Cells
Cyclooxygenase Inhibitors
Eicosanoids
Prostaglandin-Endoperoxide Synthases
Growth
Heterografts
Colorectal Neoplasms
Neoplasms
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & DuBois, R. N. (1998). Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research, 58(2), 362-366.

Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. / Sheng, Hongmiao; Shao, Jinyi; Morrow, Jason D.; Beauchamp, R. Daniel; DuBois, Raymond N.

In: Cancer Research, Vol. 58, No. 2, 15.01.1998, p. 362-366.

Research output: Contribution to journalArticle

Sheng, H, Shao, J, Morrow, JD, Beauchamp, RD & DuBois, RN 1998, 'Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells', Cancer Research, vol. 58, no. 2, pp. 362-366.
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research. 1998 Jan 15;58(2):362-366.
Sheng, Hongmiao ; Shao, Jinyi ; Morrow, Jason D. ; Beauchamp, R. Daniel ; DuBois, Raymond N. / Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. In: Cancer Research. 1998 ; Vol. 58, No. 2. pp. 362-366.
@article{f18b46fb94ae444f85769fa704f4f960,
title = "Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells",
abstract = "Previously, we have shown that forced expression of prostaglandin endoperoxide synthase-2 [also called cyclooxygenase (COX) 2] leads to inhibition of programmed cell death in intestinal epithelial cells. More recently, we have demonstrated that growth of human colonic cancer xenografts is inhibited by treatment with a highly selective COX-2 inhibitor in tumors that express COX-2 (HCA-7) but not in those that lack COX-2 expression (HCT- 116). To explore the biochemical mechanisms involved in these effects, we have evaluated the role of COX-2-derived eicosanoid products on programmed cell death in human colon cancer cells. Here we report that PGE2 treatment of human colon cancer cells leads to increased clonogenicity of HCA-7, but not HCT-116 cells. Treatment with a highly selective COX-2 inhibitor (SC- 58125) decreases colony formation in monolayer culture and this growth inhibition was reversed by treatment with PGE2. Additionally, PGE2 inhibits programmed cell death caused by SC-58125 and induces Bcl-2 expression, but did not affect Bcl-x or Bax expression in human colon cancer (HCA-7) cells. Therefore, decreased cell death caused by PGE2 would enhance the tumorigenic potential of intestinal epithelial cells. Thus, these results may help to explain a component of the mechanism by which COX inhibitors prevent colorectal cancer in humans.",
author = "Hongmiao Sheng and Jinyi Shao and Morrow, {Jason D.} and Beauchamp, {R. Daniel} and DuBois, {Raymond N.}",
year = "1998",
month = "1",
day = "15",
language = "English (US)",
volume = "58",
pages = "362--366",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells

AU - Sheng, Hongmiao

AU - Shao, Jinyi

AU - Morrow, Jason D.

AU - Beauchamp, R. Daniel

AU - DuBois, Raymond N.

PY - 1998/1/15

Y1 - 1998/1/15

N2 - Previously, we have shown that forced expression of prostaglandin endoperoxide synthase-2 [also called cyclooxygenase (COX) 2] leads to inhibition of programmed cell death in intestinal epithelial cells. More recently, we have demonstrated that growth of human colonic cancer xenografts is inhibited by treatment with a highly selective COX-2 inhibitor in tumors that express COX-2 (HCA-7) but not in those that lack COX-2 expression (HCT- 116). To explore the biochemical mechanisms involved in these effects, we have evaluated the role of COX-2-derived eicosanoid products on programmed cell death in human colon cancer cells. Here we report that PGE2 treatment of human colon cancer cells leads to increased clonogenicity of HCA-7, but not HCT-116 cells. Treatment with a highly selective COX-2 inhibitor (SC- 58125) decreases colony formation in monolayer culture and this growth inhibition was reversed by treatment with PGE2. Additionally, PGE2 inhibits programmed cell death caused by SC-58125 and induces Bcl-2 expression, but did not affect Bcl-x or Bax expression in human colon cancer (HCA-7) cells. Therefore, decreased cell death caused by PGE2 would enhance the tumorigenic potential of intestinal epithelial cells. Thus, these results may help to explain a component of the mechanism by which COX inhibitors prevent colorectal cancer in humans.

AB - Previously, we have shown that forced expression of prostaglandin endoperoxide synthase-2 [also called cyclooxygenase (COX) 2] leads to inhibition of programmed cell death in intestinal epithelial cells. More recently, we have demonstrated that growth of human colonic cancer xenografts is inhibited by treatment with a highly selective COX-2 inhibitor in tumors that express COX-2 (HCA-7) but not in those that lack COX-2 expression (HCT- 116). To explore the biochemical mechanisms involved in these effects, we have evaluated the role of COX-2-derived eicosanoid products on programmed cell death in human colon cancer cells. Here we report that PGE2 treatment of human colon cancer cells leads to increased clonogenicity of HCA-7, but not HCT-116 cells. Treatment with a highly selective COX-2 inhibitor (SC- 58125) decreases colony formation in monolayer culture and this growth inhibition was reversed by treatment with PGE2. Additionally, PGE2 inhibits programmed cell death caused by SC-58125 and induces Bcl-2 expression, but did not affect Bcl-x or Bax expression in human colon cancer (HCA-7) cells. Therefore, decreased cell death caused by PGE2 would enhance the tumorigenic potential of intestinal epithelial cells. Thus, these results may help to explain a component of the mechanism by which COX inhibitors prevent colorectal cancer in humans.

UR - http://www.scopus.com/inward/record.url?scp=0031984810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031984810&partnerID=8YFLogxK

M3 - Article

C2 - 9443418

AN - SCOPUS:0031984810

VL - 58

SP - 362

EP - 366

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -